Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2026 09:28 ET | Source: 24/7 Market News

The Multi-Billion-Dollar Search for Better Glioblastoma Treatments

Yet one of oncology's greatest challenges, Glioblastoma, remains largely unsolved.
May 22, 2026 06:05 ET | Source: Robbins Geller Rudman & Dowd LLP

TUESDAY INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The case alleges ImmunityBio materially overstated Anktiva’s capabilities.
May 13, 2026 17:20 ET | Source: Robbins Geller Rudman & Dowd LLP

INVESTOR ALERT: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RGRD Law

The case alleges ImmunityBio materially overstated Anktiva’s capabilities.
April 24, 2026 22:12 ET | Source: Robbins Geller Rudman & Dowd LLP

IBRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

The case alleges ImmunityBio materially overstated Anktiva’s capabilities.
April 13, 2026 16:01 ET | Source: Robbins Geller Rudman & Dowd LLP

INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The case alleges ImmunityBio materially overstated Anktiva’s capabilities.
April 06, 2026 07:12 ET | Source: Robbins Geller Rudman & Dowd LLP

IBRX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The case alleges ImmunityBio materially overstated Anktiva’s capabilities.
April 02, 2026 13:40 ET | Source: Robbins Geller Rudman & Dowd LLP

IBRX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The case alleges ImmunityBio materially overstated Anktiva’s capabilities.
March 30, 2026 06:40 ET | Source: Robbins Geller Rudman & Dowd LLP

INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law

The case alleges ImmunityBio materially overstated Anktiva’s capabilities.
March 27, 2026 12:17 ET | Source: Block & Leviton LLP

$IBRX Lawsuit: ImmunityBio, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses

A lawsuit has been filed against ImmunityBio. ImmunityBio investors should contact Block & Leviton to possibly recover losses from their $IBRX investment.
March 26, 2026 20:02 ET | Source: Robbins Geller Rudman & Dowd LLP

IBRX INVESTOR ALERT: ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit – RGRD Law

The case alleges ImmunityBio materially overstated Anktiva’s capabilities.